220 related articles for article (PubMed ID: 21749888)
1. A historical perspective of anthracycline cardiotoxicity.
Ewer MS; Von Hoff DD; Benjamin RS
Heart Fail Clin; 2011 Jul; 7(3):363-72. PubMed ID: 21749888
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
3. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
Ky B; Carver JR
Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
[TBL] [Abstract][Full Text] [Related]
4. Reducing the cardiotoxicity of the anthracyclines.
Carlson RW
Oncology (Williston Park); 1992 Jun; 6(6):95-100, 104, 107, discussion 107-8. PubMed ID: 1535212
[TBL] [Abstract][Full Text] [Related]
5. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
6. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of anthracycline-induced cardiotoxicity.
Jannazzo A; Hoffman J; Lutz M
Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
[TBL] [Abstract][Full Text] [Related]
9. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
Appel JM; Rybjerg M; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
[No Abstract] [Full Text] [Related]
10. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
11. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
13. Detection of anthracycline-induced cardiotoxicity.
Meinardi MT; van der Graaf WT; van Veldhuisen DJ; Gietema JA; de Vries EG; Sleijfer DT
Cancer Treat Rev; 1999 Aug; 25(4):237-47. PubMed ID: 10448132
[TBL] [Abstract][Full Text] [Related]
14. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
15. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity of anthracycline].
Wojtukiewicz MZ; Omyła J; Kozłowski L; Szynaka B
Postepy Hig Med Dosw; 2000; 54(4):467-85. PubMed ID: 11016267
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of anthracycline cardiotoxicity].
Rossetti R
Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
[No Abstract] [Full Text] [Related]
18. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
19. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity.
Germanakis I; Anagnostatou N; Kalmanti M
Pediatr Blood Cancer; 2008 Sep; 51(3):327-33. PubMed ID: 18523992
[TBL] [Abstract][Full Text] [Related]
20. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
